Overall, these results identified GM-CSF as a potential therapeutic target in subgroups of HCC patients, while raising the questions of the underlying molecular mechanisms regulating GM-CSF secretion specifically in NrasG12D/PtenKO. This evidence concerns the gene CSF2 and hepatocellular carcinoma.